Celgene ( CELG) Drug: Revlimid Abstract No. 8017 Indication: Multiple myeloma Clinical Trial: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma: CALGB 100104. Presentation Time: Sunday, June 6. Oral session. Notes: A separate and equally important study of Revlimid maintenance after stem cell transplant for myeloma will be presented during the same session.